Decorsiere, A. and H. Mueller, et al. (2016). "Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor." Nature 531(7594): 386-9.
Riviere, L. and L. Gerossier, et al. (2015). "HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase." J Hepatol.
Benhenda, S. and A. Ducroux, et al. (2013). "Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription." J Virol 87(8): 4360-71.
van Breugel, P. C. and E. I. Robert, et al. (2012). "Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates." Hepatology 56(6): 2116-24.
Lereau, M. and D. Gouas, et al. (2012). "Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells." J Gen Virol 93(Pt 3): 640-50.
Brezillon, N. and M. N. Brunelle, et al. (2011). "Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice." PLoS One 6(12): e25096.
Lucifora, J. and S. Arzberger, et al. (2011). "Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection." J Hepatol 55(5): 996-1003.
Shukla, R. and J. Yue, et al. (2011). "Proinflammatory cytokine TNF-alpha increases the stability of hepatitis B virus X protein through NF-kappaB signaling." Carcinogenesis 32(7): 978-85.
Lucifora, J. and D. Durantel, et al. (2010). "Control of hepatitis B virus replication by innate response of HepaRG cells." Hepatology 51(1): 63-72.
Gouas, D. A. and H. Shi, et al. (2010). "Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein." Carcinogenesis 31(8): 1475-82.
Villet, S. and G. Billioud, et al. (2009). "In vitro characterization of viral fitness of therapy-resistant hepatitis B variants." Gastroenterology 136(1): 168-176.e2.
Vincent, I. E. and J. Lucifora, et al. (2009). "Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro." Antivir Ther 14(1): 131-5.
Hantz, O. and R. Parent, et al. (2009). "Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells." J Gen Virol 90(Pt 1): 127-35.
Narayan, R. and B. Gangadharan, et al. (2009). "Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection." J Proteome Res 8(1): 118-22.
Martin-Lluesma, S. and C. Schaeffer, et al. (2008). "Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1." Hepatology 48(5): 1467-76.
Lucifora, J. and D. Durantel, et al. (2008). "Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector." J Gen Virol 89(Pt 8): 1819-28.
Alotte, C. and A. Martin, et al. (2008). "Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro." Antiviral Res 80(3): 280-7.
Escuret, V. and A. Martin, et al. (2006). "Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system." Antimicrob Agents Chemother 50(12): 3984-91.
Hantz, O. and F. Zoulim (2004). "Duck hepatitis B virus primary hepatocyte culture model." Methods Mol Med 96: 189-97.
Thermet, A. and M. Robaczewska, et al. (2004). "Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection." J Virol 78(4): 1945-53.
Gheit, T. and S. Sekkat, et al. (2002). "Experimental transfection of Macaca sylvanus with cloned human hepatitis B virus." J Gen Virol 83(Pt 7): 1645-9.
Delmas, J. and O. Schorr, et al. (2002). "Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro." Antimicrob Agents Chemother 46(2): 425-33.
Le Guerhier, F. and C. Pichoud, et al. (2001). "Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus." Antimicrob Agents Chemother 45(4): 1065-77.
Borel, C. and O. Schorr, et al. (2001). "Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression." Hepatology 34(1): 168-79.
Le Guerhier, F. and C. Pichoud, et al. (2000). "Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model." Antimicrob Agents Chemother 44(1): 111-22.
Hantz, O. and J. L. Kraus, et al. (2000). "Design and evaluation of hepatitis B virus inhibitors." Curr Pharm Des 6(5): 503-23.
Seigneres, B. and C. Pichoud, et al. (2000). "Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B." J Infect Dis 181(4): 1221-33.
Hantz, O. and C. Perigaud, et al. (1999). "The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo." Antiviral Res 40(3): 179-87.
Langon, T. and C. Pichoud, et al. (1998). "A novel vector for the study of hepatitis delta virus replication." J Virol Methods 70(1): 19-28.
Langon, T. and S. Fillon, et al. (1998). "Analysis of a hepatitis delta virus isolate from the Central African Republic." Res Virol 149(3): 171-85.
Hantz, O. and C. Borel, et al. (1997). "Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles." Antimicrob Agents Chemother 41(11): 2579-81.
Zoulim, F. and E. Dannaoui, et al. (1996). "2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo." Antimicrob Agents Chemother 40(2): 448-53.
Turin, F. and C. Borel, et al. (1996). "n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes." J Virol 70(5): 2691-6.
Tang, J. R. and L. Cova, et al. (1994). "Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction." J Hepatol 21(6): 953-60.
Qu, D. and O. Hantz, et al. (1994). "Heterogeneity of hepatitis C virus genotypes in France." J Gen Virol 75 ( Pt 5): 1063-70.
Chemin, I. and C. Vermot-Desroches, et al. (1994). "Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry." J Viral Hepat 1(1): 39-44.
Tang, J. R. and O. Hantz, et al. (1993). "Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic." J Gen Virol 74 ( Pt 9): 1827-35.
Chemin, I. and C. Vermot-Desroches, et al. (1993). "Monitoring of early events of experimental woodchuck hepatitis infection: studies of peripheral blood mononuclear cells by cytofluorometry and PCR." FEMS Immunol Med Microbiol 7(3): 241-9.
Chemin, I. and I. Baginski, et al. (1992). "Demonstration of woodchuck hepatitis virus infection of peripheral blood mononuclear cells by flow cytometry and polymerase chain reaction." J Gen Virol 73 ( Pt 1): 123-9.
Fourel, I. and J. Li, et al. (1992). "Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks." J Med Virol 37(2): 122-6.
Chemin, I. and C. Vermot-Desroches, et al. (1992). "Selective detection of human hepatitis B virus surface and core antigens in some peripheral blood mononuclear cell subsets by flow cytometry." J Clin Lab Immunol 38(2): 63-71.
Baginski, I. and I. Chemin, et al. (1992). "Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis." Transfusion 32(3): 215-20.
Hantz, O. and I. Baginski, et al. (1992). "Viral spliced RNA are produced, encapsidated and reverse transcribed during in vivo woodchuck hepatitis virus infection." Virology 190(1): 193-200.
Chemin, I. and I. Baginski, et al. (1991). "Correlation between HBV DNA detection by polymerase chain reaction and Pre-S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections." J Med Virol 33(1): 51-7.
Baginski, I. and I. Chemin, et al. (1991). "Detection of polyadenylated RNA in hepatitis B virus-infected peripheral blood mononuclear cells by polymerase chain reaction." J Infect Dis 163(5): 996-1000.
Fourel, I. and O. Hantz, et al. (1990). "Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks." Antimicrob Agents Chemother 34(3): 473-5.
Fourel, I. and P. Gripon, et al. (1989). "Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing." Hepatology 10(2): 186-91.
Fourel, I. and O. Hantz, et al. (1987). "Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases." Antiviral Res 8(4): 189-99.
Theze, N. and P. Gripon, et al. (1987). "Maintenance of woodchuck hepatitis virus activity in woodchuck hepatocyte primary culture." J Gen Virol 68 ( Pt 4): 1029-39.
Cova, L. and V. Lambert, et al. (1986). "Evidence for the presence of duck hepatitis B virus in wild migrating ducks." J Gen Virol 67 ( Pt 3): 537-47.
Trepo, C. and D. Ouzan, et al. (1986). "Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV." J Hepatol 3 Suppl 2: S97-105.
Trepo, C. and D. Ouzan, et al. (1986). "Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection." J Hepatol 3 Suppl 2: S129-35.
Lindberg, J. and C. Pichoud, et al. (1985). "Woodchuck hepatitis virus infection: serologic and histopathologic course and outcome." Eur J Clin Microbiol 4(1): 59-61.
Hantz, O. and T. Ooka, et al. (1984). "Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases." Antimicrob Agents Chemother 25(2): 242-6.
Frommel, D. and D. Crevat, et al. (1984). "Immunopathologic aspects of woodchuck hepatitis." Am J Pathol 115(1): 125-34.
Hantz, O. and H. S. Allaudeen, et al. (1984). "Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine." Antiviral Res 4(4): 187-99.
Stannard, L. M. and O. Hantz, et al. (1983). "Antigenic cross-reactions between woodchuck hepatitis virus and human hepatitis B virus shown by immune electron microscopy." J Gen Virol 64 (Pt 4): 975-80.
Trepo, C. and F. Degos, et al. (1983). "Serial transmission of hepatitis B like non-A, non-B hepatitis and associated markers to chimpanzees successfully immunized against HBV." Dev Biol Stand 54: 443-9.
Hantz, O. and C. Pichoud, et al. (1983). "Use of the cross-reactivity with hepatitis B virus antigens and antibodies for the demonstration of a woodchuck hepatitis virus 'e' antigen-antibody system." J Virol Methods 7(1): 45-55.
Trepo, C. and L. Vitvitski, et al. (1982). "Could hepatitis-B-like non-A non-B hepatitis simply be seronegative hepatitis B?" Lancet 1(8282): 1182.
Trepo, C. and L. Vitvitski, et al. (1981). "Detection by immunofluorescence of a new "core-like" Ag/Ab system in liver and serum of patients with NANB hepatitis." Liver 1(3): 191-200.
Trepo, C. and L. Vitvitski, et al. (1981). "Non-A, Non-B hepatitis virus: identification of a core antigen-antibody system that cross reacts with hepatitis B core antigen and antibody." J Med Virol 8(1): 31-47.
Trepo, C. and L. Vitvitski, et al. (1980). "[Non-A non-B hepatitis virus: demonstration of a double antigenic and structural kinship with hepatitis B virus]." C R Seances Acad Sci D 290(4): 343-6.
Trepo, C. and L. Vitvitski, et al. (1980). "Detection in serum of precipitating Ag/Ab system supposedly with non A non B hepatitis (N.A.N.B.)." Riv Emoter Immunoematol 27(1-2): 88-9.
Trepo, C. and L. Vitvitski, et al. (1980). "Identification and detection of long incubation non-A, non-B hepatitis virus and associated antigens or antibodies." J Virol Methods 2(1-2): 127-39.
Hantz, O. and L. Vitvitski, et al. (1980). "Non-a, non-b hepatitis: identification of hepatitis-B-like virus particles in serum and liver." J Med Virol 5(1): 73-86.
Blanchy, B. and O. Hantz, et al. (1980). "Two low molecular weight peptides as common determinants to different molecular forms and specificities of hepatitis B e antigen (HBeAg)." J Med Virol 5(1): 39-46.
Vitvitski, L. and C. Trepo, et al. (1980). "Use of the cross-reactivity between hepatitis B and non-A, non-B viruses for the identification and detection of non-A, non-B 'e' antigen." J Virol Methods 1(3): 149-56.
Hantz, O. and L. Vitvitski, et al. (1979). "[Identification of a virus similar to hepatitis B virus in non-A non-B hepatitis]." C R Seances Acad Sci D 289(16): 1263-6.
Trepo, C. and O. Hantz, et al. (1978). "Different fates of hepatitis B virus markers during plasma fractionation: a clue to the infectivity of blood derivatives." Vox Sang 35(3): 143-8.